Sven Hoffner - Concepedia

Author

Sven Hoffner

Also Known As

Afshin Moniri, S E Hoffner, S Hoffner, S. E. Hoffner, S. Hoffner, S.E Hoffner, S.E. Hoffner, Sven E Hoffner, Sven E. Hoffner, Sven Erik Hoffner

105

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

Swedish Institute Karolinska Institutet Public Health Agency of Sweden Karolinska University Hospital Research Center Borstel - Leibniz Lung Center

About

Sven Hoffner is an author at Swedish Institute specializing in tuberculosis, medicine, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	31	2.6K
2	Health Sciences	18	22	1.7K
3	Engineering	2	2	46
4	Public Health	2	2	80
5	Biochemistry	1	1	213

Sven Hoffner

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages David Stucki, Daniela Brites, Leïla Jeljeli, Nature Genetics Pulmonary TuberculosisTuberculosis PreventionTuberculosisMicrobiologyMedicine	2016	465
A standardised method for interpreting the association between mutations and phenotypic drug resistance in<i>Mycobacterium tuberculosis</i> Paolo Miotto, Belay Tessema, Elisa Tagliani, European Respiratory Journal	2017	324
Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance Abigail L. Manson, Keira A. Cohen, Thomas Abeel, Nature Genetics Medical MicrobiologyPulmonary TuberculosisAntimicrobial Resistance GeneHealth SciencesGenomic Analysis	2017	287
Effect of <i>rpoB</i> Mutations Conferring Rifampin Resistance on Fitness of <i>Mycobacterium tuberculosis</i> Deneke H. Mariam, Yohannes Mengistu, Sven Hoffner, Antimicrobial Agents and Chemotherapy Pulmonary TuberculosisAntimicrobial Resistance GeneHealth SciencesM. TuberculosisMedicine	2004	244
Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs L Barrera, E Cooreman, de Dieu Iragena J, Drug SafetyTherapeutic Drug MonitoringMedicineTuberculosisDrug Test	2008	227
Rates and Mechanisms of Resistance Development in<i>Mycobacterium tuberculosis</i>to a Novel Diarylquinoline ATP Synthase Inhibitor Emma Huitric, Peter Verhasselt, A. Koul, Antimicrobial Agents and Chemotherapy Resistant MutantsMolecular BiologyAntimicrobial ChemotherapyAntibiotic ResistanceDrug Resistance	2009	213
Spread of Drug-Resistant Pulmonary Tuberculosis in Estonia Annika Krüüner, Sven Hoffner, Heinart Sillastu, Journal of Clinical Microbiology	2001	191
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project Matteo Zignol, Anna Dean, Natavan Alikhanova, The Lancet Infectious Diseases	2016	164
Rapid and Inexpensive Drug Susceptibility Testing of <i>Mycobacterium tuberculosis</i> with a Nitrate Reductase Assay Kristian Ängeby, Lisbeth Klintz, Sven Hoffner Journal of Clinical Microbiology	2002	161
Pyrazinamide Resistance and <i>pncA</i> Gene Mutations in <i>Mycobacterium tuberculosis</i> Pontus Juréen, Jim Werngren, Juan-Carlos Toro, Antimicrobial Agents and Chemotherapy Tuberculosis PreventionMolecular BiologyPyrazinamide ResistanceAntibiotic ResistancePnca Gene Mutations	2008	143

Page 1